Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMYMP) Non-Current Assets (2016 - 2025)

Bristol Myers Squibb (BMYMP) has disclosed Non-Current Assets for 17 consecutive years, with $60.6 billion as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 3.46% to $60.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $245.0 billion through Dec 2025, down 8.08% year-over-year, with the annual reading at $60.6 billion for FY2025, 3.46% down from the prior year.
  • Non-Current Assets for Q4 2025 was $60.6 billion at Bristol Myers Squibb, down from $61.3 billion in the prior quarter.
  • The five-year high for Non-Current Assets was $85.3 billion in Q1 2021, with the low at $60.6 billion in Q4 2025.
  • Average Non-Current Assets over 5 years is $68.9 billion, with a median of $67.5 billion recorded in 2023.
  • The sharpest move saw Non-Current Assets dropped 14.55% in 2022, then rose 4.71% in 2024.
  • Over 5 years, Non-Current Assets stood at $76.1 billion in 2021, then decreased by 8.55% to $69.5 billion in 2022, then dropped by 8.85% to $63.4 billion in 2023, then dropped by 0.89% to $62.8 billion in 2024, then dropped by 3.46% to $60.6 billion in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $60.6 billion, $61.3 billion, and $61.5 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.